CLGN
CollPlant Biotechnologies Ltd
OpenVolumeMkt capP/EEPSDiv yield
Day – 52-wk –
Expected move
InputsNext report
Last report
—
Largest filed tie
13F top-10 QoQ
Top fund weight
—
CollPlant Biotechnologies Ltd
Expected move
InputsNext report
Last report
—
Largest filed tie
13F top-10 QoQ
Top fund weight
—
No changes.
No changes.
Same SIC code · 6
Same SEC industry code: Intuitive Surgical Inc, Edwards Lifesciences Corp, Steris plc and 3 more; no measured co-movers for CollPlant Biotechnologies Ltd.
Same SIC code · 6
Same SEC industry code: Intuitive Surgical Inc, Edwards Lifesciences Corp, Steris plc and 3 more; no measured co-movers for CollPlant Biotechnologies Ltd.
Annual filing, covered
20-F parsed · Mar 26 '26
Supply-chain ties, covered
Disclosed · both directions
Fund holders, covered
No N-PORT holders
13F holdings, covered
13F quarter · Jun 30 '26
Management, not covered
Not covered · DEF 14A, 8-K 5.02
Company IR feed, not covered
News via newswires & EDGAR
Products, patents, hiring, not covered
Not covered
Annual filing, covered
20-F parsed · Mar 26 '26
Supply-chain ties, covered
Disclosed · both directions
Fund holders, covered
No N-PORT holders
13F holdings, covered
13F quarter · Jun 30 '26
Management, not covered
Not covered · DEF 14A, 8-K 5.02
Company IR feed, not covered
News via newswires & EDGAR
Products, patents, hiring, not covered
Not covered
No thesis.
| Manager | Value | % base | |
|---|---|---|---|
| Pinnacle | $255,277 | 43.76% | +32.97% |
| Villere ST Denis J | $211,572 | 36.27% | −0.15% |
| Brown Advisory | $36,541 | 6.26% | −11.79% |
| Renaissance Technologies | $21,457 | 3.68% | +266.07% |
| Pathstone | $19,888 | 3.41% | 0.00% |
| Manager | Value | % base | |
|---|---|---|---|
| Pinnacle | $255,277 | 43.76% | +32.97% |
| Villere ST Denis J | $211,572 | 36.27% | −0.15% |
| Brown Advisory | $36,541 | 6.26% | −11.79% |
| Renaissance Technologies | $21,457 | 3.68% | +266.07% |
| Pathstone | $19,888 | 3.41% | 0.00% |
+16.06%
shares held · 10 largest managers
CollPlant Biotechnologies Ltd., a regenerative and aesthetic medicine company, focuses on three-dimensional (3D) bioprinting of tissues and organs, and medical aesthetics in the United States, Canada, and Europe. Its products are based on recombinant type I human collagen that is produced with its proprietary plant based genetic engineering technology. The company's products include BioInks for 3D printing of tissues and organs; dermal filler and soft tissue fillers for treating wrinkles; 3D Bioprinted breast implants for regeneration of breast tissue; injectable implants to promote breast tissue regeneration; 3D bioprinted regenerative soft tissue matrix; VergenixSTR, a soft tissue repair matrix intended for the treatment of tendinopathy; and VergenixFG, an advanced wound care product for the treatment of deep surgical incisions and wounds, including diabetic ulcers, venous and pressure ulcers, burns, bedsores, and other chronic wounds. It has collaboration agreements with 3D Systems Corporation; CellInk, a BICO Group company; Advanced Regenerative Manufacturing Institute; RegenMed Development Organization; Israel's Technion Institute of Technology; AbbVie; and STEMCELL. The company was formerly known as CollPlant Holdings Ltd. and changed its name to CollPlant Biotechnologies Ltd. in June 2019. CollPlant Biotechnologies Ltd. was founded in 2004 and is headquartered in Rehovot, Israel.
CollPlant Biotechnologies Ltd., a regenerative and aesthetic medicine company, focuses on three-dimensional (3D) bioprinting of tissues and organs, and medical aesthetics in the United States, Canada, and Europe. Its products are based on recombinant type I human collagen that is produced with its proprietary plant based genetic engineering technology. The company's products include BioInks for 3D printing of tissues and organs; dermal filler and soft tissue fillers for treating wrinkles; 3D Bioprinted breast implants for regeneration of breast tissue; injectable implants to promote breast tissue regeneration; 3D bioprinted regenerative soft tissue matrix; VergenixSTR, a soft tissue repair matrix intended for the treatment of tendinopathy; and VergenixFG, an advanced wound care product for the treatment of deep surgical incisions and wounds, including diabetic ulcers, venous and pressure ulcers, burns, bedsores, and other chronic wounds. It has collaboration agreements with 3D Systems Corporation; CellInk, a BICO Group company; Advanced Regenerative Manufacturing Institute; RegenMed Development Organization; Israel's Technion Institute of Technology; AbbVie; and STEMCELL. The company was formerly known as CollPlant Holdings Ltd. and changed its name to CollPlant Biotechnologies Ltd. in June 2019. CollPlant Biotechnologies Ltd. was founded in 2004 and is headquartered in Rehovot, Israel.
News
Linked news
Expected move
No implied move.
CollPlant Biotechnologies Ltd
4.29
+0.21 · +5.07%
post 4.24 −1.09%